NasdaqGS - Nasdaq Real Time Price USD

Sanofi (SNY)

49.36

+2.75

(+5.90%)

At close: April 25 at 4:00 PM EDT

48.49

-0.87

(-1.76%)

Pre-Market: 7:40 AM EDT

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Investor's Business Daily 15 hours ago

AZN
+5.38%
SNY
+5.90%
CELG-RT
Sanofi (SNY) Q1 2024 Earnings Call Transcript

SNY earnings call for the period ending March 31, 2024.

Motley Fool 18 hours ago

SNY
+5.90%
20 Fastest Growing Health Tech Companies in the World

In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]

Insider Monkey 20 hours ago

TDOC

SNY
+5.90%
GSK
+0.12%
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Zacks 20 hours ago

SNY
+5.90%
AZN
+5.38%
Sanofi Sales, Profit Beat Expectations

Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new drug launches.

The Wall Street Journal yesterday

SNY
+5.90%
SNYNF
UPDATE 2-Sanofi profit slips on generic competition and currency effects

Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

Reuters yesterday

SNY
+5.90%
Sanofi profit slips on generic competition and currency effects

(Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

Reuters yesterday

SNY
+5.90%
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performa

GlobeNewswire yesterday

SNY
+5.90%
SNYNF
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Zacks yesterday

ABBV

SNY
+5.90%
CELG-RT
Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff

(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with the matter, one of the biggest deals likely to happen in Europe this year. Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Soars as Musk’s Cheaper EVs Calm Fears Ove

Bloomberg 2 days ago

SNY
+5.90%
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Zacks 2 days ago

SNY
+5.90%
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele

GlobeNewswire 3 days ago

SNY
+5.90%
SNYNF
Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer

Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer

PREMIUM
MT Newswires 3 days ago

SNY
+5.90%
Sanofi to overhaul US operations of vaccines, cut jobs

Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.

Reuters 7 days ago

SNY
+5.90%
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS

GlobeNewswire 9 days ago

SNY
+5.90%
SNYNF
Sanofi: Information concerning the total number of voting rights and shares - March 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

GlobeNewswire 13 days ago

SNY
+5.90%
SNYNF
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

COMBINED GENERAL MEETING OF APRIL 30, 2024 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday April 30, 2024 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the we

GlobeNewswire 17 days ago

SNY
+5.90%
SNYNF
10 Best Weight Loss Drug Stocks to Buy Now

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

Insider Monkey 19 days ago

LLY
-1.00%
NVO
-0.29%
VKTX
UPDATE 2-Cyclicals drive modest gains across European stocks

The continent-wide STOXX 600 index closed up 0.2%, led by a 1.7% gain in the basic resources sector as copper prices hit their highest in more than 14 months. "Recent inflation trends in Europe stand in stark contrast to what is happening in the U.S.," as per strategists at BCA Research. "This divergence in inflationary dynamics will force the ECB to be more dovish than the Fed."

Reuters 22 days ago

SNY
+5.90%
Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer

The French healthcare company said the deal would require the consent of individual plaintiffs and would take time to conclude.

The Wall Street Journal 22 days ago

SNY
+5.90%
SNYNF

Performance Overview

Return	SNY	CAC 40
YTD	-0.74%	+6.63%
1-Year	-10.43%	+6.79%
3-Year	+6.89%	+28.53%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (SNY)

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

Sanofi (SNY) Q1 2024 Earnings Call Transcript

20 Fastest Growing Health Tech Companies in the World

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

Sanofi Sales, Profit Beat Expectations

UPDATE 2-Sanofi profit slips on generic competition and currency effects

Sanofi profit slips on generic competition and currency effects

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer

Sanofi to overhaul US operations of vaccines, cut jobs

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Sanofi: Information concerning the total number of voting rights and shares - March 2024

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

10 Best Weight Loss Drug Stocks to Buy Now

UPDATE 2-Cyclicals drive modest gains across European stocks

Sanofi to Settle Claims That Heartburn Drug Zantac Caused Cancer

Performance Overview